Literature DB >> 6323548

Heterotypic reactions in a radioimmunoassay for coxsackie B virus specific IgM.

S F Pugh.   

Abstract

IgM antibody capture radioimmunoassays were developed to detect coxsackie virus B1-B5 specific IgM. Specific IgM was detected in sera from all patients with coxsackie B virus infections proved by isolation; however, sera from 13/32 patients with rising neutralising antibody titres were negative in the assay. Frequent heterotypic responses were seen among the positive sera. Thirty seven patients with other enterovirus infections were also studied, and sera from 15 of these patients reacted in the assay, showing that heterotypic coxsackie B IgM responses occur not only in coxsackie B virus infections but also in other enterovirus infections.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323548      PMCID: PMC498746          DOI: 10.1136/jcp.37.4.433

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

1.  Studies on the antibody responses of patients infected with ECHO viruses.

Authors:  N J SCHMIDT; J DENNIS; S J HAGENS; E H LENNETTE
Journal:  Am J Hyg       Date:  1962-03

2.  Studies on the routine laboratory diagnosis of coxsackie group B virus infections. I. The application of tissue culture procedures.

Authors:  A J GIRARDI; K HUMMELER; I OLSHIN
Journal:  J Lab Clin Med       Date:  1957-10

3.  Counterimmunoelectrophoresis test for immunoglobulin M antibodies to group B coxsackievirus.

Authors:  T E Minor; P B Helstrom; D B Nelson; D J D'Alessio
Journal:  J Clin Microbiol       Date:  1979-04       Impact factor: 5.948

4.  Characterization of antibodies produced in natural and experimental coxsackievirus infections.

Authors:  N J Schmidt; E H Lennette; J Dennis
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

5.  Coxsackie-B-virus-specific IgM responses in patients with cardiac and other diseases.

Authors:  M M El-Hagrassy; J E Banatvala; D J Coltart
Journal:  Lancet       Date:  1980-11-29       Impact factor: 79.321

6.  Association of group B coxsackie viruses with cases of pericarditis, myocarditis, or pleurodynia by demonstration of immunoglobulin M antibody.

Authors:  N J Schmidt; R L Magoffin; E H Lennette
Journal:  Infect Immun       Date:  1973-09       Impact factor: 3.441

7.  Coxsackie-B-virus-specific IgM responses in children with insulin-dependent (juvenile-onset; type I) diabetes mellitus.

Authors:  M L King; A Shaikh; D Bidwell; A Voller; J E Banatvala
Journal:  Lancet       Date:  1983-06-25       Impact factor: 79.321

8.  Specificity of IgM antibodies in acute human coxsackievirus B infections, analysed by indirect solid phase enzyme immunoassay and immunoblot technique.

Authors:  R Dörries; V ter Meulen
Journal:  J Gen Virol       Date:  1983-01       Impact factor: 3.891

9.  Comparison of prolactin levels in human semen and seminal plasma.

Authors:  W A Luqman; L A Matej; M L Smith
Journal:  J Endocrinol       Date:  1979-04       Impact factor: 4.286

10.  Antibody capture radioimmunoassay (MACRIA) for coxsackievirus B4 and B5-specific IgM.

Authors:  P Morgan-Capner; C McSorley
Journal:  J Hyg (Lond)       Date:  1983-06
View more
  4 in total

1.  Subclass restriction of human enterovirus antibodies.

Authors:  E G Torfason; C B Reimer; H L Keyserling
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

2.  Non-polio enteroviruses and motor neurone disease.

Authors:  P G Kennedy; E J Bell; S A Keane; M C Timbury
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

3.  Comparative evaluation of immunoglobulin M neutralizing antibody response in acute-phase sera and virus isolation for the routine diagnosis of enterovirus infection.

Authors:  B Pozzetto; O G Gaudin; M Aouni; A Ros
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

4.  BK virus specific IgM responses in cord sera, young children and healthy adults detected by RIA.

Authors:  D W Brown; S D Gardner; P E Gibson; A M Field
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.